JP2010516639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516639A5 JP2010516639A5 JP2009545828A JP2009545828A JP2010516639A5 JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5 JP 2009545828 A JP2009545828 A JP 2009545828A JP 2009545828 A JP2009545828 A JP 2009545828A JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- carcinoma
- tumor
- sarcoma
- gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 201000009047 Chordoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 208000004064 acoustic neuroma Diseases 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 3
- 201000002222 hemangioblastoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 208000025189 neoplasm of testis Diseases 0.000 claims description 3
- 201000008026 nephroblastoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000004560 pineal gland Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002861 ventricular Effects 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 208000025750 heavy chain disease Diseases 0.000 description 2
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- 208000018964 sebaceous gland cancer Diseases 0.000 description 2
- 201000008759 sweat gland cancer Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000026005 Central nervous system vascular disease Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HNZQTDJRORNUGH-UHFFFAOYSA-N N-butyl-2,4-dihydroxy-N-methyl-5-[4-(2-methylphenyl)-5-oxo-1H-1,2,4-triazol-3-yl]benzamide Chemical compound C1=C(O)C(C(=O)N(C)CCCC)=CC(C=2N(C(O)=NN=2)C=2C(=CC=CC=2)C)=C1O HNZQTDJRORNUGH-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007002715A DE102007002715A1 (de) | 2007-01-18 | 2007-01-18 | Triazolderivat |
| DE102007002715.1 | 2007-01-18 | ||
| PCT/EP2007/010775 WO2008086857A1 (de) | 2007-01-18 | 2007-12-11 | Triazolderivat als hsp 90 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010516639A JP2010516639A (ja) | 2010-05-20 |
| JP2010516639A5 true JP2010516639A5 (enExample) | 2011-02-03 |
| JP5266253B2 JP5266253B2 (ja) | 2013-08-21 |
Family
ID=39345628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545828A Expired - Fee Related JP5266253B2 (ja) | 2007-01-18 | 2007-12-11 | Ｈｓｐ９０阻害剤としてのトリアゾール誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8816070B2 (enExample) |
| EP (1) | EP2102175B1 (enExample) |
| JP (1) | JP5266253B2 (enExample) |
| KR (1) | KR20090101381A (enExample) |
| CN (1) | CN101583605B (enExample) |
| AR (1) | AR064951A1 (enExample) |
| AU (1) | AU2007344512B2 (enExample) |
| BR (1) | BRPI0720956A2 (enExample) |
| CA (1) | CA2675737C (enExample) |
| CL (1) | CL2008000134A1 (enExample) |
| DE (1) | DE102007002715A1 (enExample) |
| EA (1) | EA015366B1 (enExample) |
| EC (1) | ECSP099586A (enExample) |
| ES (1) | ES2455504T3 (enExample) |
| MX (1) | MX2009007479A (enExample) |
| MY (1) | MY151452A (enExample) |
| NZ (1) | NZ579069A (enExample) |
| PE (1) | PE20090051A1 (enExample) |
| TW (1) | TW200838502A (enExample) |
| UA (1) | UA98320C2 (enExample) |
| WO (1) | WO2008086857A1 (enExample) |
| ZA (1) | ZA200905700B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008287367B2 (en) | 2007-08-13 | 2012-02-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2490688B1 (en) * | 2009-10-19 | 2014-10-08 | Synta Pharmaceuticals Corp. | Combination cancer therapy with hsp90 inhibitory compounds |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| DE102010024338A1 (de) | 2010-06-18 | 2011-12-22 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid |
| PL2623499T3 (pl) * | 2010-10-01 | 2015-09-30 | Taisho Pharmaceutical Co Ltd | Pochodne 1,2,4-triazolonu |
| DK2670404T3 (en) * | 2011-02-02 | 2018-11-19 | Univ Princeton | CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| CN106478531B (zh) * | 2015-08-25 | 2019-06-28 | 南京华威医药科技集团有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸中间体 |
| KR20210021457A (ko) * | 2018-05-14 | 2021-02-26 | 리아타 파마슈티컬즈, 아이엔씨. | 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드 |
| CN115006395B (zh) * | 2022-04-29 | 2023-03-14 | 佛山病原微生物研究院 | 一种xl888在制备用于抗腺病毒感染的药物中的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| AU3378599A (en) | 1998-04-03 | 1999-10-25 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| EP1161231A2 (en) | 1999-03-12 | 2001-12-12 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Method of inhibiting a chaperone protein |
| CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| AU2001271567A1 (en) | 2000-06-29 | 2002-01-14 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| JP2004504356A (ja) | 2000-07-20 | 2004-02-12 | メルク エンド カムパニー インコーポレーテッド | Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制 |
| ATE526019T1 (de) | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| ATE374753T1 (de) | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| US20050020556A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| US20050054589A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics |
| US20050054625A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors |
| US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| US20050020557A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
| EP1817295B1 (en) * | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
-
2007
- 2007-01-18 DE DE102007002715A patent/DE102007002715A1/de not_active Withdrawn
- 2007-12-11 NZ NZ579069A patent/NZ579069A/en not_active IP Right Cessation
- 2007-12-11 MY MYPI20092959 patent/MY151452A/en unknown
- 2007-12-11 EP EP07856537.1A patent/EP2102175B1/de active Active
- 2007-12-11 MX MX2009007479A patent/MX2009007479A/es active IP Right Grant
- 2007-12-11 US US12/523,387 patent/US8816070B2/en active Active
- 2007-12-11 JP JP2009545828A patent/JP5266253B2/ja not_active Expired - Fee Related
- 2007-12-11 UA UAA200908637A patent/UA98320C2/ru unknown
- 2007-12-11 KR KR1020097016991A patent/KR20090101381A/ko not_active Withdrawn
- 2007-12-11 AU AU2007344512A patent/AU2007344512B2/en not_active Ceased
- 2007-12-11 BR BRPI0720956-8A patent/BRPI0720956A2/pt not_active IP Right Cessation
- 2007-12-11 ES ES07856537.1T patent/ES2455504T3/es active Active
- 2007-12-11 CN CN2007800499639A patent/CN101583605B/zh not_active Expired - Fee Related
- 2007-12-11 CA CA2675737A patent/CA2675737C/en active Active
- 2007-12-11 WO PCT/EP2007/010775 patent/WO2008086857A1/de not_active Ceased
- 2007-12-11 EA EA200900913A patent/EA015366B1/ru not_active IP Right Cessation
-
2008
- 2008-01-16 CL CL200800134A patent/CL2008000134A1/es unknown
- 2008-01-17 TW TW097101845A patent/TW200838502A/zh unknown
- 2008-01-17 PE PE2008000150A patent/PE20090051A1/es not_active Application Discontinuation
- 2008-01-18 AR ARP080100223A patent/AR064951A1/es unknown
-
2009
- 2009-08-17 EC EC2009009586A patent/ECSP099586A/es unknown
- 2009-08-17 ZA ZA200905700A patent/ZA200905700B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516639A5 (enExample) | ||
| Sun et al. | Natural berberine-hybridized benzimidazoles as novel unique bactericides against Staphylococcus aureus | |
| Tan et al. | Azolylpyrimidinediols as novel structural scaffolds of DNA-groove binders against intractable Acinetobacter baumannii | |
| Peri et al. | Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update: miniperspective | |
| WO2007130383A3 (en) | Compositions and treatments using pyridazine compounds and secretases | |
| BR0311291A (pt) | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
| Chai et al. | Potential succinate dehydrogenase inhibitors bearing a novel pyrazole-4-sulfonohydrazide scaffold: molecular design, antifungal evaluation, and action mechanism | |
| MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
| JP2018534301A (ja) | 新規ガラクトシドによるガレクチン阻害剤 | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| Ali et al. | Dihydropyrazole derivatives act as potent α-amylase inhibitors and free radical scavengers: synthesis, bioactivity evaluation, structure–activity relationship, ADMET, and molecular docking studies | |
| Lutfiya et al. | Molecular docking and interactions between vascular endothelial growth factor (VEGF) receptors and phytochemicals: An in-silico study | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| Pernak et al. | Conversion of quinine derivatives into biologically active ionic liquids: Advantages, multifunctionality, and perspectives | |
| BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
| JP5759000B2 (ja) | 肝疾患治療の薬物の製造におけるジインドリルメタン及びその前駆体並びにその誘導体の応用 | |
| Faião-Flores et al. | DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1, 4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment | |
| JP2019501948A (ja) | 化学療法で誘導される末梢神経障害の治療に使用するためのｉｌ−８阻害剤 | |
| Ozdemir et al. | Synthesis, anticonvulsant and antimicrobial activities of some new [1-(2-naphthyl)-2-(pyrazol-1-yl) ethanone] oxime ethers | |
| Sharma et al. | Curcumin analogs as anti-cathepsins agents: Designing, virtual screening, and molecular docking analysis | |
| Brahmbhatt et al. | Synthesis, characterization, antibacterial and antioxidant potency of N-substituted-2-sulfanylidene-1, 3-thiazolidin-4-one derivatives and QSAR study | |
| Silva et al. | Antibacterial and antibiotic modifying activity of chalcone (2E)-1-(4′-aminophenyl)-3-(4-methoxyphenyl)-prop-2-en-1-one in strains of Staphylococcus aureus carrying NorA and MepA efflux pumps: in vitro and in silico approaches | |
| Rizvi et al. | The flavonoid hesperidin methyl chalcone as a potential therapeutic agent for cancer therapy: molecular docking, in vitro cytotoxicity, and in vivo antitumor activity | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2019519464A5 (enExample) |